Beta Bionics Earnings Call Signals Growth and Investment

Beta Bionics, Inc. ((BBNX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Beta Bionics, Inc. delivered an upbeat 2025 earnings call, underscoring rapid top-line growth, strong adoption of its iLet system and expanding high-margin pharmacy revenue, even as management acknowledged a recent FDA warning letter and rising costs. Executives struck a confident tone on remediation, liquidity and the longer-term roadmap, while signaling some near-term margin and seasonality pressures.

Explosive Revenue Growth in 2025

Full-year 2025 net sales surged to $100.3 million, a 54% jump versus the prior year, confirming strong momentum for the company’s diabetes technology platform. Fourth-quarter sales grew even faster, rising 57% year over year to $32.1 million, highlighting a robust exit rate heading into 2026.

Rapid Expansion of the iLet User Base

Beta Bionics added close to 20,000 new iLet users during 2025, more than doubling the installed base it had at the start of the year. Since launch, the total installed base has reached roughly 35,000 users, underscoring accelerating adoption among people with insulin-dependent diabetes.

New Patient Starts Remain Strong

In the fourth quarter, the company recorded 5,592 new patient starts, up 37% from a year earlier and 5% sequentially, signaling sustained demand despite a tough macro backdrop. Management noted that the full-year mix of new starts included a high contribution from the pharmacy channel, reinforcing the shift toward recurring revenue.

Gross Margin Expansion from Scale and Mix

For 2025, gross margin inched up to 55.4%, reflecting better scale and manufacturing leverage as volumes rose. In Q4, gross margin reached 59%, up 179 basis points year over year, aided by growing high-margin pharmacy recurring revenue and operational efficiencies.

Pharmacy Channel and PBM Coverage Deepen

The pharmacy channel gained significant traction, with the share of new patient starts reimbursed through pharmacy rising to the high-20s percent for 2025 from high single digits a year earlier. In the fourth quarter, pharmacy accounted for a low-30s percent of new starts, supported by formulary agreements with all major PBMs and coverage for about 80% of insured lives.

Recurring Revenue and Strong Patient Retention

Management emphasized that pharmacy-installed users generate attractive recurring revenue, citing around $450 in monthly ARR per pharmacy patient. They also highlighted strong retention in both DME and pharmacy channels, suggesting durable utilization and a growing base of predictable, high-margin supply sales.

Balance Sheet Strength Supports Investment

As of December 31, 2025, Beta Bionics held roughly $265 million in cash, cash equivalents and investments, providing ample capital to fund its commercial and R&D priorities. Leadership argued this liquidity positions the company to reach free-cash-flow generation ahead of many peers in the diabetes-device space.

Pipeline Progress: Mint and Bihormonal System

The Mint patch-pump program remains on track for an unconstrained commercial launch by the end of 2027, reinforcing the company’s multi-product strategy in automated insulin delivery. Meanwhile, Beta Bionics completed a first-in-human feasibility trial of its bihormonal system and a PK/PD study for its glucagon asset, with additional Phase IIa and Phase IIb trials planned ahead of pivotal studies.

FDA Warning Letter Spurs Quality Overhaul

The company received a warning letter in January tied to a 2025 FDA inspection, with findings focused on complaint handling, MDR reportability, tracking and CAPA effectiveness, including certain software updates. Management said remediation is underway, expects older filings to be addressed by the end of the second quarter and does not see the issue altering its broader timelines.

Operating Expenses Climb with Growth Investments

Fourth-quarter operating expenses rose to $35.1 million, a 42% increase from $24.7 million a year ago, as the company ramped sales and marketing, R&D for Mint and the bihormonal program and public-company infrastructure. Executives cautioned that both OpEx and CapEx will rise as a percentage of revenue in 2026 as these growth investments accelerate.

Pharmacy Mix Creates Near-Term Margin Drag

While strategically attractive, faster pharmacy adoption can pressure near-term revenue and margins because iLet hardware is provided free in that channel and economics are captured over time through recurring supplies. Management guided 2026 gross margin to 55.5%–57.5% and flagged particular pressure in the first quarter as pharmacy mix increases.

Seasonal Weakness Expected in Q1 Revenue

Executives said they expect first-quarter 2026 revenue to decline sequentially from Q4 2025, driven largely by seasonal deductible resets that typically slow new starts and refill patterns. They added that the step-down from Q4 to Q1 will likely be more pronounced than the prior year, a factor investors will watch in the near term.

Reduced Granularity on New Patient Metrics

Beta Bionics plans to stop disclosing exact quarterly new patient start figures, a change that trims a previously detailed operational metric closely followed by analysts. The company will still report revenue by product and channel, pharmacy mix and commentary on trends, but investors will have less precise visibility into patient-add momentum.

Elevated MDR Rate During Remediation Phase

As part of its quality remediation, the company has reclassified some past complaints under updated reportability definitions, leading to retroactive MDR filings. Management warned that the MDR reporting rate will remain elevated through at least the second quarter as this process continues, though they stressed this reflects administrative clean-up rather than new safety issues.

Deliberate Sales Force Expansion Strategy

Beta Bionics ended the fourth quarter with 63 sales territories and plans to add at least 20 more in 2026, weighted toward the first half. Leadership described the build-out as deliberate rather than aggressive, balancing market coverage gains against cost discipline and the need to maintain productivity per rep.

Guidance and Outlook Emphasize Growth with Investment

For full-year 2026, the company guided revenue to $130–$135 million, with 36%–38% of new patient starts expected via the pharmacy channel and gross margin of 55.5%–57.5%. Management expects Q1 revenue and margins to dip sequentially before gross margin improves each quarter, while OpEx and CapEx will rise as a share of sales to fund Mint, the bihormonal program and a roughly 30% expansion in sales territories.

Beta Bionics’ call painted a picture of a high-growth diabetes-tech player leaning into recurring pharmacy revenue and a rich pipeline, underpinned by a solid balance sheet. Investors will need to look past short-term margin, seasonality and quality-remediation noise, but the company’s confident outlook and 2026 guidance suggest management sees the current investment phase setting up for sustained long-term value creation.